Get the Stockscreener App
7.95
2.21%
-0.18
Pre-market:
7.66
-0.29
-3.65%
Entrada Therapeutics Inc stock is traded at $7.95, with a volume of 276.21K.
It is down -2.21% in the last 24 hours and down -24.21% over the past month.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
See More
Previous Close:
$8.13
Open:
$7.98
24h Volume:
276.21K
Relative Volume:
2.13
Market Cap:
$297.75M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
2.6858
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
+0.38%
1M Performance:
-24.21%
6M Performance:
-54.10%
1Y Performance:
-34.57%
1-Day Range:
$7.88
$8.185
1-Week Range:
$7.56
$8.375
52-Week Range:
$7.10
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
7.95 | 297.75M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
LPL Financial LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Trend Tracker for (TRDA) - news.stocktradersdaily.com
Vanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
CandE Benchmark Research Case Study – Entrada Therapeutics - ere.net
KLP Kapitalforvaltning AS Invests $36,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
American Century Companies Inc. Purchases 8,985 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? - Yahoo Finance
HC Wainwright Issues Negative Forecast for TRDA Earnings - MarketBeat
Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop - simplywall.st
HC Wainwright Issues Pessimistic Forecast for TRDA Earnings - Defense World
(TRDA) On The My Stocks Page - news.stocktradersdaily.com
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - Defense World
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals - TipRanks
Entrada Therapeutics stock rating holds with $20 target By Investing.com - Investing.com UK
Entrada Therapeutics stock hits 52-week low at $9.74 By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Roth/MKM maintains Buy on Entrada stock, $23 target By Investing.com - Investing.com Canada
Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment - TipRanks
Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK (TRDA:NASDAQ) - Seeking Alpha
Entrada Therapeutics rises on UK approval for muscle-wasting drug study - TradingView
Entrada’s ENTR-601-45 gains clearance in UK to enter clinic for Duchenne muscular dystrophy - BioWorld MedTech
Entrada Therapeutics begins Duchenne study in UK By Investing.com - Investing.com Australia
Entrada Therapeutics begins Duchenne study in UK - Investing.com India
Entrada Therapeutics Gains UK Approval for DMD Study - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - The Manila Times
Major Breakthrough: Entrada's DMD Drug Gets Green Light for UK Clinical Trials - Stock Titan
Bank of New York Mellon Corp Lowers Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics stock hits 52-week low at $10.21 - Investing.com
Entrada Therapeutics stock hits 52-week low at $10.21 By Investing.com - Investing.com UK
Entrada Therapeutics CFO sells $19,035 in stock By Investing.com - Investing.com South Africa
Entrada Therapeutics CFO sells $19,035 in stock - Investing.com India
Long Term Trading Analysis for (TRDA) - news.stocktradersdaily.com
Entrada Therapeutics stock hits 52-week low at $10.25 By Investing.com - Investing.com Australia
Entrada Therapeutics stock hits 52-week low at $10.25 - Investing.com
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday - Defense World
Entrada Therapeutics stock hits 52-week low at $11.3 amid market shifts - Investing.com Canada
Brokers Offer Predictions for TRDA Q4 Earnings - Defense World
What is William Blair’s Estimate for TRDA Q1 Earnings? - Defense World
Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next - Yahoo
Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat
Entrada Therapeutics' (TRDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating - TipRanks
Entrada Therapeutics reports Q4 EPS 3c vs. (29c) last year - TipRanks
Oppenheimer maintains Entrada stock Outperform with $30 target - Investing.com
Oppenheimer maintains Entrada stock Outperform with $30 target By Investing.com - Investing.com South Africa
Entrada Therapeutics Reports Strong 2024 Financial Results - TipRanks
Entrada Therapeutics earnings beat by $0.70, revenue fell short of estimates - Investing.com UK
Entrada Therapeutics sees cash runway into 2Q27 - TipRanks
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):